Winst gevend schreef op 22 augustus 2020 15:47:
Biocryst APEX 3 scored ZERO attacks in HAE.
In APeX-2, 31 participants who were assigned randomly to receive 150 mg of berotralstat
(taken daily by mouth) have completed 48 weeks (about a year) of treatment.
Prior to the start of the trial, at baseline, these participants had an average HAE attack rate of 2.9 attacks per month.
After one month of treatment, this rate decreased to 1.5 attacks per month, and after a year to 1.0 attack per month.
In APeX-S, 73 participants have completed 48 weeks of treatment at the same dose (150 mg per day).
In six of the twelve months of the study, the median number of
attacks per month was zero.Als Ruconest is bedoeld als opvang-medicijn lijkt het nu al op einde verhaal voor Pharming?